Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Azelnidipine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1C known ✓ | Q13936 | 3/20 | 0.53 |
| ▸ | CACNA1F known ✓ | O60840 | 2/20 | 0.53 |
| ▸ | CACNA1D known ✓ | Q01668 | 2/20 | 0.53 |
| ▸ | CACNA1S known ✓ | Q13698 | 2/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.97 |
| ▸ | MEN1 | O00255 | 3/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.97 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.97 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.97 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.97 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.97 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.97 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.97 |
| ▸ | MLNR | O43193 | 1/20 | 0.97 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.97 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.97 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Azelnidipine SCHEMBL4160407 | 0.99 | ADORA3 (0.98) | ADORA3MEN1KMT2ANR1I2AGTR1 | |
| Azelnidipine SCHEMBL4422517 | 0.99 | ADORA3 (0.98) | ADORA3MEN1KMT2ANR1I2AGTR1 | |
| Azelnidipine SCHEMBL27968844 | 0.99 | ADORA3 (0.98) | ADORA3MEN1KMT2ANR1I2AGTR1 | |
| Azelnidipine SCHEMBL27962226 | 0.99 | ADORA3 (0.98) | ADORA3MEN1KMT2ANR1I2AGTR1 | |
| Azelnidipine SCHEMBL4171605 | 0.98 | ADORA3 (0.97) | ADORA3MEN1KMT2ANR1I2AGTR1 | |
| Azelnidipine SCHEMBL49021 | 0.98 | ADORA3 (1.00) | ADORA3MEN1KMT2ANR1I2AGTR1 | |
| Azelnidipine SCHEMBL3092194 | 0.98 | ADORA3 (1.00) | ADORA3MEN1KMT2ANR1I2AGTR1 | |
| Azelnidipine SCHEMBL29349688 | 0.98 | ADORA3 (1.00) | ADORA3MEN1KMT2ANR1I2AGTR1 | |
| SCHEMBL7272814 | 0.98 | ADORA3 (1.00) | ADORA3MEN1KMT2ANR1I2AGTR1 | |
| Azelnidipine SCHEMBL3098831 | 0.98 | ADORA3 (1.00) | ADORA3MEN1KMT2ANR1I2AGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1961751-B1 | ACID ADDITION SALT OF OPTICALLY ACTIVE DIHYDROPYRIDINE DERIVATIVE | UBE INDUSTRIES (JP) | 2012-11-21 | — | — | EP | disclosed |
| US-20090170826-A1 | Acid Addition Salt of Optically Active Dihydropyridine Derivative | DAIICHI SANKYO COMPANY ,LIMITED (JP) | 2009-07-02 | — | — | US | disclosed |
| EP-1961751-A1 | ACID ADDITION SALT OF OPTICALLY ACTIVE DIHYDROPYRIDINE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2008-08-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170826-A1 | Acid Addition Salt of Optically Active Dihydropyridine Derivative | REN, QDPR, DNPEP | CACNA1C 238/4885CACNA1F 443/4885CACNA1D 215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.